RavasioR., AntonelliS., MaiorinoA., CostanzoA., & LosiS. (2019). Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Global & Regional Health Technology Assessment, 6(1). https://doi.org/10.33393/grhta.2019.468